TEMOVATE SUMMARY
TEMOVATE (clobetasol propionate emollient cream)
Emollient, 0.05%
TEMOVATE (clobetasol propionate cream and ointment) Cream and Ointment contain the active compound clobetasol propionate, a synthetic corticosteroid, for topical dermatologic use. Clobetasol, an analog of prednisolone, has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity.
TEMOVATE Cream and Ointment are super-high potency corticosteroid formulations indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Use in pediatric patients under 12 years of age is not recommended.
As with other highly active corticosteroids, therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary.
|
NEWS HIGHLIGHTSMedia Articles Related to Temovate (Clobetasol Topical)
Atopic Dermatitis
Source: MedicineNet mupirocin Specialty [2008.06.03]
Title: Atopic Dermatitis
Category: Diseases and Conditions
Created: 12/31/1997
Last Editorial Review: 6/3/2008
Published Studies Related to Temovate (Clobetasol Topical)
Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial. [2009.08.03]
Summary Background Mastocytosis is characterized by the accumulation and activation of mast cells in different organs, most commonly the skin. Miltefosine, a raft modulator, has recently been shown to inhibit the activation of mast cells and to reduce mast cell-driven skin inflammatory responses...
Short-contact clobetasol propionate shampoo 0.05% improves quality of life in patients with scalp psoriasis. [2009.03]
Scalp psoriasis has a considerable impact on the quality of life (QOL) of patients, and most patients are dissatisfied with available treatments. Clobetasol propionate shampoo 0.05% has been shown to be effective and safe for moderate to severe scalp psoriasis... Therefore, we conclude that treatment with clobetasol propionate shampoo improved the QOL of participants and resulted in high satisfaction.
Valacyclovir and topical clobetasol gel for the episodic treatment of herpes labialis: a patient-initiated, double-blind, placebo-controlled pilot trial. [2009.03]
BACKGROUND: Treatment of herpes simplex labialis (HSL) has been associated with modest benefits. This difficulty results from the rapid resolution of the disease accomplished by the immune system, which narrows the window of therapeutic opportunity. The immune response is also responsible for important clinical manifestations, including oedema and pain. The dual role of immune responses (protection, pathology) is well recognized in other infectious diseases. The addition of corticosteroids to antimicrobial agents has been associated with improvement in some of these diseases. OBJECTIVE: We evaluated the combination of oral valacyclovir plus topical clobetasol compared to placebo for recurrent HSL... CONCLUSIONS: This pilot study supports the addition of topical corticosteroids to an oral antiviral agent for the treatment of HSL. Larger studies need to confirm the safety and efficacy of this approach.
Topical clobetasol in the treatment of atrophic-erosive oral lichen planus: a randomized controlled trial to compare two preparations with different concentrations. [2009.02]
Oral lichen planus (OLP) is a chronic inflammatory disease that can be painful, mainly in the atrophic and erosive forms. Numerous drugs have been used with dissimilar results, but most treatments are empirical and do not have adequate control groups or correct study designs...
Valacyclovir and topical clobetasol gel for the episodic treatment of herpes labialis: a patient-initiated, double-blind, placebo-controlled pilot trial. [2009.01.08]
Abstract Background Treatment of herpes simplex labialis (HSL) has been associated with modest benefits. This difficulty results from the rapid resolution of the disease accomplished by the immune system, which narrows the window of therapeutic opportunity...
Clinical Trials Related to Temovate (Clobetasol Topical)
A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam [Completed]
Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis [Completed]
Evaluation of the effectiveness of Clobex® Spray, 0. 05% when used as monotherapy or add-on
therapy to existing systemic or topical anti-psoriatic agents.
Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis [Completed]
Maintenance Effect of Clobex Shampoo on Subjects With Moderate to Severe Scalp Psoriasis [Completed]
The objective of the study is to assess the maintenance effect on scalp psoriasis of Clobex®
Shampoo 0. 05% when used twice weekly.
Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis [Not yet recruiting]
This clinical trial will evaluate the efficacy and safety of Clobex® (clobetasol propionate)
Spray 0. 05% and Vectical™ (calcitriol) Ointment 3 µg/g over a four week period of use in one
of two different regimens:
1. Vectical™ Ointment treatment, twice daily on weekdays (Mon - Fri) and Clobex® Spray treatment twice daily on weekends (Sat - Sun) for 28 days
2. Clobex® Spray each morning and Vectical™ Ointment once each evening for 28 days
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 2 ratings/reviews, Temovate has an overall score of 7. The effectiveness score is 6 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
| | Temovate review by 46 year old female patient | | | Rating |
| Overall rating: | |   |
| Effectiveness: | | Moderately Effective |
| Side effects: | | No Side Effects | | |
Treatment Info |
| Condition / reason: | | dyshidrosis |
| Dosage & duration: | | twice daily (dosage frequency: twice daily) for the period of two weeks |
| Other conditions: | | noce |
| Other drugs taken: | | None | | |
Reported Results |
| Benefits: | | The resulting small, fluid-filled blisters (vesicles) most commonly occur on the palms and fingers of your hands and on the soles and toes of your feet. The blisters usually last for three to four weeks.
The blisters often cause intense itching. Scratching the blisters can damage the skin and, in some cases, lead to infection. Once the blisters dry, they often leave cracks and painful grooves (fissures) in your skin.
Risk factors
Dyshidrosis occurs twice as often in women as in men. Other risk factors include:
* Stress, because dyshidrosis appears to be more common during times of stress
* Exposure to metal salts, such as chromium, cobalt and nickel — usually through cement or mechanical work
* Having seasonal allergies, such as hay fever
* Frequently exposing your skin to water or other wet substances
|
| Side effects: | | The resulting small, fluid-filled blisters (vesicles) most commonly occur on the palms and fingers of your hands and on the soles and toes of your feet. The blisters usually last for three to four weeks.
The blisters often cause intense itching. Scratching the blisters can damage the skin and, in some cases, lead to infection. Once the blisters dry, they often leave cracks and painful grooves (fissures) in your skin.
Risk factors
Dyshidrosis occurs twice as often in women as in men. Other risk factors include:
* Stress, because dyshidrosis appears to be more common during times of stress
* Exposure to metal salts, such as chromium, cobalt and nickel — usually through cement or mechanical work
* Having seasonal allergies, such as hay fever
* Frequently exposing your skin to water or other wet substances
|
| Comments: | | The resulting small, fluid-filled blisters (vesicles) most commonly occur on the palms and fingers of your hands and on the soles and toes of your feet. The blisters usually last for three to four weeks.
The blisters often cause intense itching. Scratching the blisters can damage the skin and, in some cases, lead to infection. Once the blisters dry, they often leave cracks and painful grooves (fissures) in your skin.
Risk factors
Dyshidrosis occurs twice as often in women as in men. Other risk factors include:
* Stress, because dyshidrosis appears to be more common during times of stress
* Exposure to metal salts, such as chromium, cobalt and nickel — usually through cement or mechanical work
* Having seasonal allergies, such as hay fever
* Frequently exposing your skin to water or other wet substances
|
|
| | Temovate review by 49 year old male patient | | | Rating |
| Overall rating: | | |
| Effectiveness: | | Moderately Effective |
| Side effects: | | No Side Effects | | |
Treatment Info |
| Condition / reason: | | Dyshidrosis |
| Dosage & duration: | | 0.05% (dosage frequency: 2x per day) for the period of 2 weeks |
| Other conditions: | | None |
| Other drugs taken: | | None | | |
Reported Results |
| Benefits: | | reduced symptoms after using the cream for a total of two months. |
| Side effects: | | There were no apparent side effect from using this treatment. |
| Comments: | | cream applied twice per day for two weeks. one week without treatment and than two weeks on the treatment. Repeat this regiment until symptoms are reduced or disappear. |
|
|
|
Page last updated: 2009-10-20
|
